OBJECTIVES: Today vaccination for children from 0 to 20 months in the Russian Federation is carried mainly by DPT and monovalent vaccines. As a result, a child of this age receives 12 injections. Vaccination against Hib infection so far is only available for children at risk (approx. 20%). Introdution of DTaP-IPV-Hib combined  vaccine could reduce the number of injections received by the child and increase the coverage against Hib infection from 20% to 97%. The objective of the present study is to assess the economic evaluation of DTaP-IPV-Hib vaccine introduction into immunization schedule and select the most cost-effective vaccination scheme  against Hib infection. METHODS: A cost-effectiveness analysis of the DTaP-IPV-Hib vaccine is performed  on suggested Markov model. The four vaccination schemes are intercompared : the current immunization program (Scheme0), a 3+1 immunization DTaP-IPV-Hib vaccine  (Scheme P), а mixed DTwP /DTaP-IPV-Hib immunization (Scheme mix) and a potential scenario - the current scheme, but with expanded (97%) Hib coverage - Scheme 1. The cohort of infants born in 2011 year is followed over their lifetime. Direct and indirect medical costs are measured  from the perspective of the public payer.  Outcomes are measured in life years gained (LYG).Exchange rate is 1€ = 41 rub. RESULTS: According to the model, total costs of immunization Scheme are:  0 – 4216723519 rub. (102 846 915€), Scheme 1 –4924823829 rub.(120 117 654€), Scheme P  -6035132925rub.(147 198 364€), Scheme mix - 4 921 824 835 rub (120 044 508€). Тhe values of cost/LYG  are estimated at 4243 198 rub .(103493€) for Scheme 0, 1 224 270rub.(29860€)for Scheme 1, 1500 283 rub. (36592€) for Scheme P, 1223 525rub.(29842€)– for Scheme mix. CONCLUSIONS: The introduction of DTaP-IPV-Hib combined vaccine would bring improvement into the Russian immunization program through a Scheme mix.